Research spotlights early signs of disease using infrared light: New research Science Daily Produced from the cell membranes of mammals, microvesicles play a role in cell communication and carry a "cargo" of RNA, DNA, proteins, lipids and other biomolecules that they use to dramatically change the biochemistry of other cells. Microvesicles ... |
Original post:
Research spotlights early signs of disease using infrared light: New research - Science Daily
POPSUGAR | Sarah Drew: Jackson and April Will "Always Be Each Other's 'Person'" POPSUGAR Jackson and April have made a breakthrough on Grey's Anatomy. After all their ups and downs, all it takes is a trip to Montana to rekindle everything they had before. We had a feeling things would go this way when Sarah Drew spoke about the episode ... Sarah Drew Asked Grey's Anatomy to Include a Breast Pump Scene, and We're All for It 22 Things We Learned From the 'Grey's Anatomy' PaleyFest Panel Grey's Anatomy Round Table: Will What Happened In Montana, Stay in Montana? |
See original here:
Sarah Drew: Jackson and April Will "Always Be Each Other's 'Person'" - POPSUGAR
GLG has produced a new series of videos focused on decision-making in the business world.
As part of the series, GLG, the world's leading membership network for professional learning, has interviewed a number of business leaders to ask about what considerations go into making important decisions.
In this installment, GLG speaks with former Pfizer Inc. (NYSE: PFE) CEO Jeff Kindler.
Kindler said a key ingredient in his meteoric rise was an open mind.
I started saying I should be open to whatever comes along, Kindler said. And that led me down all kinds of different paths I never would have predicted.
Kindler joined Pfizer as the pharma giants general council, but he admits that he had always had ambitions to be CEO. Once he assumed the role, he was presented with an opportunity to work with former President Barack Obama on the Affordable Care Act (ACA).
Kindler said many of the provisions being discussed at the time were politically polarizing but would have been universally bad for the pharmaceutical industry. Rather than fight the change, Kindler and a handful of other pharma CEOs decided to take a more constructive approach.
We formed a small group of five of us who were CEOs of different companies in pharmaceuticals with different interests and a different focus, and we decided that within the right boundaries, if we could achieve acceptable policy solutions, we would support the bill, Kindler recalled.
To this day, there are people who dont like what we did, even within the pharmaceutical industry. But my view is I got attacked by both the Wall Street Journal and the New York Times editorial page, and I think when that happens you know youre in the sweet spot.
Kindler sees his participation in the process as a valuable lesson in the power of compromise. While the pharmaceutical industry made a number of financial sacrifices as part of the process, he and his colleagues were also able help shape the bill to maximize potential industry benefits.
Kindler said the success of Obamacare to this day depends on perspective. In terms of increasing health insurance coverage, the program was a complete success. In terms of fixing the underlying problems of rising healthcare costs, Kindler believes Obamacare hasnt delivered.
He closed the interview by discussing one key regret he has about his time as CEO.
I think I fell prey to something thats in human nature, which is I didnt block enough time for personal development. I think a lot of [people] that are Type A personalities end up in big jobs, and theyre so focused on both the fact that they have achieved that and the things that they need to do on it that they just dont pay attention enough to the things that are of long-term importance.
Kindler said time management, prioritization and mentorship were three of the biggest challenges of such an important professional role.
Related Link:
6 Outsider CEO Hires That Flopped
Posted-In: Anatomy of a Decision Barack Obama GLGNews Education Management Media General Best of Benzinga
2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Continue reading here:
Anatomy Of A Decision, Part 1: The C-Suite - Benzinga
Clara suffers from rare, fatal genetic disorder
The race to find a cure for a rare genetic disease has become a Hoover family's mission as they try to save their little girl. "A Cure for Clara," may come from of all places Auburn University's College of Veterinary Medicine.
Everything appeared normal when Baby Clara came into the world. By 14 months though, she was lagging behind in development. "Our first red flag, she wasn't walking," explains her mom Jenny Bragg. Then the heartbreaking diagnosis came last August. Clara had GM1 gangliosidosis which is an inherited disorder. It destroys nerve cells.
"She was terminal; they said there was nothing they could do for her and we should go home and enjoy our time with her," recalls Bragg with tears in her eyes. She and her husband scoured the internet looking for something, any hope.
That lead them to Auburn University and groundbreaking research at the College of Veterinary Medicine. GM1 had been cured in cats and the researchers were preparing for human clinical trials. The gene therapy involves a single IV injection.
A research cat named Cinnamon who was treated is now seven years old. Others have also been cured. "They could live a normal life span. Showing this treatment works in animals is the first step to see if it's applicable to humans," explains Auburn Researcher and Professor Doug Martin, Ph.D.
The remarkable results hold promise for curing other fatal diseases. "If we can find the gene that causes Huntington's disease, Lou Gehrig's disease, the same basic technique and approach can be used," says Martin.
Human trials are set for six children including Clara if she stays healthy in November at the National Institutes of Health in Bethesda, Maryland. "I do have apprehension . on the other hand it's our only shot saving her life," says Jenny Bragg.
To make sure those human trials happen another $400,000 needs to be raised. A special fundraiser is set for Saturday, April 8th at the Redmont Hotel: Clara's Birthday Bash.
For more information go to:
ACureforClara.com
All the proceeds go to the Cure GM1 Foundation.
Original post:
A Cure for Clara: Gene therapy developed at Auburn University set for human trials - Alabama's News Leader
Forbes | Chemistry And Beyond: Three Keys To A Successful CMO-Branding Agency Relationship Forbes Many factors contribute to a successful rebrand solid research, stellar creativity, a strategic launch plan and more. But here's one critical factor that's often overlooked: the relationship between the branding firm and the CMO. A productive ... |
Read more from the original source:
Chemistry And Beyond: Three Keys To A Successful CMO-Branding Agency Relationship - Forbes
Not a week passes without reproducibility in science or the lack of it hitting the headlines. Although much of the criticism is directed at the biomedical sciences or psychology, many of the same problems also pervade the chemical sciences.
A survey of over 1500 scientists conducted by Nature last year revealed that 70% of researchers think that science faces a reproducibility crisis. Over half, however, still have faith in published literature in their field with chemists being amongst the most confident despite reporting the most difficulty replicating other researchers or their own work. Although this observation seems contradictory, an explanation might be that chemists are more often looking to repeat experiments exactly, says Rick Danheiser, a synthetic organic chemist at the Massachusetts Institute of Technology.
Chemical journal articles suffer from the inability of people to name compounds accurately
Anita Bandrowski, University of California, San Diego
Danheiser is the editor-in-chief of the unconventional journal Organic Syntheses that has verified the experiments of all the papers it has published since it launched in 1921. The journal does this by having the research replicated by independent chemists before publishing them a practice that is almost unheard of in chemistry or any other research field (the exception being a few brief instances in history). All experiments are checked for reproducibility in the lab of one of the journals board of editors, often by graduate students and postdoctoral researchers working under the supervision of the Organic Syntheses editor. Danheiser, who has written about reproducibility, tells Chemistry World that the journal usually aims to check the work in submitted papers within six months.
But Danheiser says that rolling out this replication process to other fields is challenging as biology often has too many variables and physics and some areas of chemistry entails the use of specialised or costly equipment that may not be readily available in other labs. Between 2010 and 2016, the journal rejected 7.5% of submissions due to irreproducibility of yield or selectivity, Danheiser notes. Most chemists would consider that to be frightening, he adds, as papers in conventional journals are therefore less likely to be reproducible.
Chemistry is to some extent in a sweet spot when it comes to reproducing experiments as the apparatus used is usually not too exotic, notes Derek Lowe, a medicinal chemist who pens the In the pipeline blog. But he notes that, for instance, in natural product chemistry almost none of the multi-step syntheses used to produce the compound are a feasible way of getting to the product. As a result, most are never completely reproduced in the first place, explains Lowe. In fact, he says, products are often easy enough to obtain from their original source in most cases. What people do build on, Lowe says, is the unique techniques researchers use when creating compounds.
Medicinal chemistry and drug discovery literature are some of the more reproducible fields in chemistry, adds Lowe, as theyre more extensively conducted by industry scientists, who have fewer incentives to publish fake or substandard results. Lowe points out that industry researchers contribute more to patent literature, and patents lacking reproducibility and rigour could result in legal issues.
Chemistrys reproducibility problem should be a fairly easy thing to fix
Phil Baran, Scripps Research Institute
Furthermore, Lowe believes irreproducibility is a bigger problem at high profile journals publishing cutting edge research, as well as low-end journals. Most solid papers are likely to be in what Lowe calls middle journals those that are respectable, but not glamorous.
This month, the Chemical Probes Portal saw its 275th compound added. This portal is part of the campaign to make science more reproducible and holds a database of many of the small molecules used in drug discovery and to investigate biological processes. The problems being addressed by the portal are twofold, says Amy Donner, its director in Boston. The smaller problem, she says, is that of making sure appropriate reagents are used in experiments. Whereas the larger issue that results in a tremendous amount of irreproducibility that we see in the literature is misunderstanding how to use these highly potent chemical probes to tweak biological processes in living organisms.
Donner says the number of chemical probes out there is in the tens of thousands, and that in itself is a problem. Biologists who are most likely to use probes in experiments dont necessarily have the expertise to carry out relevant chemical validation tests to determine which molecules would work best in their experiments, says Donner. This is where the chemical probes portal comes into its own offering advice on which probes are suitable for specific circumstances and which are best avoided. Researchers can search their target protein and find a list of molecules that interact with it, Donner explains.
Theres currently no checklist outlining a compounds information rather, says Donner, scientists rely on aggregating information about probes as they go. Sharing that information on the portal should save others from replicating that effort as well as informing investigators how they should be designing experiments taking into account a probes strengths and weaknesses.
But the portal is still in its infancy and researchers face a huge task logging tens of thousands more molecules, Donner says. At present, the priority is highlighting the best and worst probes. In the short term, thats how we can have the biggest impact, she adds.
Research Resource Identifier (RRID) is another initiative with the goal of improving research reproducibility by helping to standardise how reagents, software, antibodies and model organisms are cited in the literature. Although over 200 journals have already started encouraging authors to use RRIDs to cite laboratory resources, chemistry journals are, on the whole, not on board yet, says Anita Bandrowski, a neuroscientist at the University of California, San Diego, who is coordinating the RRID project.
According to Bandrowski, chemical journal articles also suffer from the inability of people to name compounds accurately. As its difficult to teach everyone to use appropriate nomenclature, says Bandrowski, attention has mostly focused on pushing researchers to at least use numerical identifiers like the PubChem ID. Our findings show that authors are highly accurate when they provide this type of information, she says.
Another phenomenon that has taken industrial chemistry by storm is electronic laboratory notebooks (ELNs), which store experimental data and procedures, allowing researchers to access data years after it was collected. One feature of ELNs is that they allow researchers to search molecular structures of reactants and products, making it easier to keep track of reactions. Inside a research group or a company, ELNs may be set up to allow scientists to search their colleagues notebooks, which is useful to avoid duplicating work and assess differences in repeat experiments. But ELNs have seen slower uptake in academia probably due to their high costs.
There are many ELNs out there with different ways of collecting and storing data, says Richard Whitby, an organic chemist at the University of Southampton, UK, who leads the Dial-a-molecule network, which aims to speed up the process of synthesising new molecules. One of the networks other goals is to promote a standard for ELN data to enable exchange and data mining. ELNs which are designed for chemistry pay you back for using them, Whitby adds. He notes that they also have some useful features such as stoichiometry calculations and experimental safety data, which partly makes up for the fact that its actually more difficult to use an ELN than a paper notebook.
Phil Baran, a synthetic organic
chemist at the Scripps Research Institute in La Jolla, California, says that blogging at the Open Flask has helped his group tackle issues like reproducibility and transparency around experiments. Weve gotten more use out of this than conventional peer review, Baran notes. He says chemistrys reproducibility problem compared with other fields should be a fairly easy thing to fix. The solution, he says, is to put the onus on authors to make their supporting information clear and to encourage them to collaborate with other labs to get their work checked or field-tested. Journals should also make rules specific to different disciplines, and text only supporting information should no longer be allowed, particularly for methodology papers where the primary outcome is for others to reproduce a protocol, Baran says.
See original here:
Taking on chemistry's reproducibility problem - Chemistry World (subscription)
As part of one of my projects, there is a /chemistry/ simulator. It's not intended to be exact to real-life chemistry, but is still a fair bit more complex than just "A + B = C" This is being done in an Object-Oriented programming language similar to java and c#.
Some background: Before I started working on the project:
The container was an instantiated object. It contained a variable, with an array of instantiated chemicals that *existed in the container*. The chemicals themselves were instantiated objects, with a reference to their container, and a volume.
Whenever the container was interacted with, (such as a new chemical added), the function would instantiate a new chemical, add linking references, and update the volume of the chemical. Then it would iterate through *EVERY* chemical in the container to check for possible reactions using a lookup table, and if a match was found, it would run the reaction, and restart. This included a potential for infinitely 'reacting' chemicals, but the workaround was just careful implementation of recipes to prevent infinite loops.
----------------------------------
Now i saw this, and was absolutely disgusted. And changed it to something more akin to:
In this model, the container has a 2D array of the chemical, and it's volume inside of the container. The chemical is only ever instantiated ONCE, and if a chemical is accessed, the properties of the master chemical are read.
(Each unique chemical has static properties in both models, and the only dynamic variable was *volume*)
Then when the contents of the container are modified, it is *flagged* to receive an update, iterates through the contents, performs all currently possible reactions unless that reaction was already performed during this update. If any reactions occured, it would flag the container to be updated *next* process. This removed the potential for problems caused be recursive reactions, but prevented instantaneous consecutive reactions.
-----------------
The problem!
NOW, i want to add some more realism and complexity to the system, as well as make it more efficient if possible. I want to iterate as infrequently as possible.
containers now store the following variables and properties regarding its chemical contents:
Quantity - The quantity of a chemical within. Equivalent to moles. Thermal Energy - The total thermal energy of chemicals within. Equivalent to joules. Volume - The volume of the container. This is the *SAME* as the total volume of the container's contents. But the volume of each chemical should also be tracked separately. ie. 50 unit container contains 30 units of AIR and 1 unit of OIL and 19 units of WATER. This should be calculated based on the quantity of each substance in the container, the temperature, and the total volume of the container. As well as some data based on the individual chemical's properties. Temperature - This is calculated based on the thermal energy, and the chemical properties of the chemicals within. (IE. Temperature = Total thermal energy / Total specific heat capacity of chemicals.) Pressure - This is calculated based on volume, temperature, quantity, and some chemical properties.
----------
What is the most efficient way for me to *add* or *remove* a chemical from the container?
For example "I add 30 units of water. This displaces the gas in the container, and modifies the specific heat and thermal energy of the container. As a result, modifying the temperature, volume, and pressure of the container contents."
How can i adjust all relevant container values using *just* the values before the water is added, and the properties of the water? What additional information might i need to store?
The volume of the contents of the container is *ALWAYS* equal to the volume of the container. This means that if the container is sealed, and contains 30 units of water @ standard temperature, but the volume of the container is *larger* than the volume of liquid water. How do i find the equilibrium point for the volume of *liquid* water and water *vapour*using only temperature, quantity, total volume, and a single extra variable/coefficient for vapour pressure?
How do i quickly and efficiently calculate that, when there are say, n other chemicals inside the container with different properties, that also need to be in equilibrium?
---
Are there any faster and more efficient methods i can use to look-up all possible reaction matches, and perform the reactions, so that the reactions are in equilibrium?
IE if i have : "1 water + 1 agent A = volatile acid" and "1 water + 1 agent B = volatile explosive" in the recipe list, and i have: "1 water, 1 agent A, and 1 agent B" in the container,
How can i make sure that i end up with 25% acid, 25% explosive, 25% A, 25% B, instead of 50% acid, 50% agent B, with as few iterations as possible?
In the case that "acid" and "explosive" react together to form 3 parts agent C and 1 part water, How can i make the reaction find equilibrium *IN THIS UPDATE*, in as few iterations as possible?
Edited by nullie, Today, 09:39 PM.
See the original post:
HALP! Simultaneous Equations with Chemistry and Physics Simulation - GameDev.net
SAN GABRIEL, California, March 20, 2017 /PRNewswire/ --
ChineseInvestors.com (CIIX) ('CIIX' or the 'Company'), the premier financial information website for Chinese-speaking investors, today announces that it has established and registered XiBiDi Biotechnology Co., Ltd. in the Pudong Free-Trade Area in Shanghai, with registered capital requirements of $1.45 million USD over the next 10 years. XiBiDi Biotechnology will focus on the online and offline sales of health products including hemp-derived CBD (cannabidiol) oil, as well as hemp-based food and beverages. Notably, the Chinese character 'XiBiDi' is homophonic to 'CBD' in English.
"I am delighted about the establishment and registration of our new hemp company," says CIIX founder and CEO, Warren Wang. "XiBiDi Biotechnology is strategically located in the Pudong Free-Trade Area of Shanghai, China, where we have the opportunity to reach a consumer base of nearly 1.4 billion people. We believe that this large population affords XiBiDi an outstanding opportunity to be the provider of choice for natural hemp products."
XiBiDi Biotechnology will be the operator of CIIX's recently launched CBD online store, http://www.ChineseCBDoil.com, which will primarily focus on selling, where legal, hemp-based CBD nutrient and health products to Chinese-speaking customers worldwide through the online retail process. CIIX is also in preparations to open a retail store based in the predominantly Chinese community of San Gabriel, California.
The establishment of XiBiDi Biotechnology supplements these ventures as well as the company's broader mission to develop its presence in the hemp industry. In addition to retail and direct sales, the company will focus on the legal import of hemp-based (but not CBD oil products) health products in China - a population increasingly interested in the health benefits of hemp and CBD oil - and the export of hemp food and beverages to the United States, Canada and Europe.
"As the aging population in China increases, Chinese people are paying more attention to their health; thus, we believe that the development of the health industry has a very bright future. CIIX is very excited to be the world's first U.S. publicly traded company promoting hemp-based CBD health products and hemp foods that will help Chinese people improve their overall health. In addition, being located in the Pudong Free-Trade Area provides great convenience for the company's future import and export business as China enacts various measures to support the development of the Pudong Free-Trade Area," concludes Wang.
XiBiDi Biotechnology is registered as a wholly foreign enterprise and the registration is expected to be completed by the end of March.
About ChineseInvestors.com (CIIX)
Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational-related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based CBD health products via its new website: http://www.ChineseCBDoil.com.
For more information visit http://www.ChineseInvestors.com
Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom
Follow us on Twitter for real-time company updates: https://twitter.com/ChineseFNEnglsh
Like us on Facebook to receive live feeds:https://www.facebook.com/Chinesefncom
Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.
Forward-looking Statement
Our discussion may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading 'Risk Factors'.
Contact: ChineseInvestors.com, Inc. 227 W. Valley Blvd, #208 A, San Gabriel, CA 91776
Investor Relations: Alan Klitenic +1-214-636-2548
Corporate Communications: NetworkNewsWire (NNW) New York, New York http://www.NetworkNewsWire.com 212-418-1217 Office Editor@NetworkNewsWire.com
Read this article:
ChineseInvestors.com Launches XiBiDi Biotechnology to Reach ... - Yahoo Finance
Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning
The continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively.
Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment.
To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example.
iland haveworked with many companies in the healthcare, life sciences and biotech industries. Therefore, it knowsfrom experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world.
>See also:10 trends that will influence cloud computing in 2017
For example, ilandrecently worked with a US based biotechnology organisation on their backup and disaster recovery (DR) strategy, and were able to drive global data centre consolidation with host-based replication to the cloud. As a result, itsDR testing and auditing processes were greatly simplified and streamlined which drove significant cost savings as well as compliance assurance.
If you still need convincing here are three additional key benefits that cloud brings to biotech organisations.
When the Human Genome Project began it was one of the most extensive research projects in the field to date costing billions of pounds and lasting over a decade.
These days, thanks largely to cloud technology, it can be done in just 26 hours. Things such as drug R&D, clinical research as well as a whole host of other areas have benefited just as much from the rapid growth of computational power. The better your technology is at crunching huge sets of data, the quicker you can innovate.
Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning.
Labs can also benefit from immense computing power without the cost and complexity of running big onsite server rooms. They can also scale up at will in order to make use of new research and ideas almost instantly.
Concerns have been voiced that so called scientific computing in the cloud may make results less reproducible. One concern is that cloud computing will be a computing black box that obscures details needed to accurately interpret the results of computational analyses.
>See also:How cloud computing can transform the pharmaceutical industry
In actual fact, by leveraging the application program interfaces (APIs) in the iland cloud, biotech customers are able to integrate cloud data back into on-premises IT systems to ensure that data analyses done in the cloud can be easily shared and consumed by other applications.
Essentially, cloud computing services bring more players to the table to solve the giant puzzle. Its a win-win situation from an economic and patient standpoint, and several big name companies are jumping on the biotech cloud bandwagon.
Biotech companies need to maintain strong access and authentication controls, while also being able to collaborate easily. For this reason audit trails and other measures are often required to verify that information has not been improperly altered, and that good experimental and manufacturing procedures have been followed.
At the same time bio-technologists need to be able to access and share data across multiple departments or even multiple companies.
Cloud computing in biotechnology makes this all possible it centralises data, ensuring security and data sovereignty while facilitating collaboration.
It supports extensive user and role based access control, two-factor authentication and integrity monitoring to prevent improper access and changes. In addition to data encryption, vulnerability scanning and intrusion detection, these measures facilitate security and compliance, without disrupting the internal workflow.
Complex regulatory requirements and logistics combined with niche markets make efficiency paramount within biotechnology. Even minor mistakes as a result of sloppy process management can easily result in major issues.
Real-time operational reporting dramatically improves efficiency, quality control and decision making, allowing organisations to react instantly to challenges and opportunities, both internal and external.
>See also:Managed cloud: making the most out of public cloud computing
As well as enhanced billing visibility and resource management functions, the release of the vendors secure cloud services means that the itscloud now includes on-demand security and compliance reports.
This advanced cloud management functionality is designed to foster strategic, self-sufficient control of a cloud environment, optimising overall cloud usage and costs to drive business initiatives and growth.
Without a shadow of a doubt, cloud technology can help biotechnology companies build the future. From research and development to marketing, computing affects everything an organisation does.
Sourced by Monica Brink, director of marketing, iland
Read more:
Exploring the cloud laboratory: biotechnology and cloud computing - Information Age
Supplied Content (Edited)
Auckland, March 20, 2017
The Auckland Bioengineering Institute (ABI) of the University of Auckland hopes to develop new international strategic partnerships and investor opportunities for medical technology (medtech).
The Institutes Strategic Partnership Specialist Dr Diana Siew said that she would focus on promoting Medtech Core and Consortium for Medical Device Technologies (CMDT), the latter founded by her with ABI Director Distinguished Professor Peter Hunter to reduce the isolation of medical technology research institutions in New Zealand.
CMDT is a partnership led of the University of Auckland with the Canterbury University, Otago University, Auckland University of Technology, Victoria University of Wellington and Callaghan Innovation.
High Achiever
ABI announced today the appointment of Dr Siew as its Strategic Partnership Specialist, stating that she has a strong innovation, research management and relationship management background in New Zealands medical technology sector.
She will continue in her role as the Co-Chair of CMDT and Associate Director of Medtech Core. She is an alumnus of the University of Auckland with a doctorate in Chemistry with several years of experience in New Zealands Medtech environment, including previous roles with Industrial Research Ltd and Callaghan Innovation.
Feedback from multinationals was that they found it hard to work in New Zealand with its large number of different research organisations in the medical health technology space. They sometimes did not know where to start to find all the people for a particular focus, Dr Siew said.
CMDT partners have developed Consortium as a national network to highlight New Zealands medtech activity and connect companies, the research industry, health providers and government stakeholders.
It is the NZ Inc front for medtech research in this country and makes it easier for multinational companies to work in New Zealand.
Trust and Transparency
Medtech Core is a translational research pipeline of new technologies for the medtech sector. ABI has created a high level of trust in the network and transparency between the partners.
Earlier this month, the CMDT partners hosted a workshop for a group of Japanese researchers, companies and funders to support a collaboration between the two countries, focused on developing new technologies for elderly care.
While working at Callaghan Innovation, Dr Siew established Standing Trial Population Centres that support fast early-stage validation studies of medical devices and digital health systems to accelerate technology development for both health and economic outcomes.
Quick validation
This platform accelerates the ability of a medtech company to get quick validation for prototypes and concepts that on which they are working. This reduces the time and expense in identifying clinical expertise and recruiting patients, she said.
It is an easy access tool for multinationals to see the four main areas where the Standing Trials Population Centres operate in technologies for elderly care, rehabilitation innovation and remote community care, and design and development for new devices.
Waikato District Health Boards Institute of Healthy Ageing and AUT are key partners to two of the Standing Trials Populations Centres.
Another initiative developed by Dr Siew for medtech is a showcase on the latest technologies available in New Zealand.
These Technology Innovation Knowledge and Interchange (TIKI) tours focus on the latest innovations for busy clinicians in health boards and other health organisations. The TIKI tours are intended to be a discussion platform between clinicians at district health boards and New Zealand health tech innovators. It is about alerting clinicians to what technologies are coming out both from industry and research institutions, so that they are aware of these for use in our health system, Dr Siew said.
*
Photo Caption:
Diana Siew
Go here to see the original:
Global partnerships brewing at bioengineering institute ... - Indian NewsLink
Variety | 'Grey's Anatomy' Cast on Saving Lives for 13 Seasons and Counting Variety When the Grey's Anatomy cast visited PaleyFest at the Dolby Theatre to a packed house of 2,500 fans, the panel was an affectionate look at where the characters have been and where they might be headed in their thirteenth season on ABC. Fans got an ... Ellen Pompeo reveals why she's stayed with 'Grey's Anatomy' for 12 years Grey's Anatomy: Caterina Scorsone Is Just as Frustrated with Amelia as Fans Are Ellen Pompeo Explains Why She's Stayed On Grey's Anatomy All These Years |
Read the rest here:
'Grey's Anatomy' Cast on Saving Lives for 13 Seasons and Counting - Variety
NASCARs version of March Madness didnt involve a buzzer-beater and a small school few recognized toppling one of college basketballs blueblood programs. Nevertheless what transpired Sunday at Phoenix International Raceway certainly qualifies as an upset, a reminder of what can transpire when circumstances converge resulting in an unforeseen outcome.
If prior to the Camping World 500 you were to draw up a list of potential winners, Ryan Newmans name certainly would not have been among the first dozen or so chosen. Thats what happens when you havent won in 127 races, while your team, Richard Childress Racing, has gone winless in the past 112 races with neither showing much indication of snapping their streaks of futility.
For much of Sunday, the fourth Monster Energy Cup Series played out as expected. Pole-sitter Joey Logano dominated early in winning the first stage, with promising second-year driver Chase Elliott asserting himself in the second stage. Then, Kyle Busch seized control in the decisive final stage.
At no point before the final two laps did it appear Newmans name would be etched on the winners trophy.
But the race that had seemingly been so clear-cut took an entirely different focus when Loganos overheated right-front tire exploded, sending him crashing into the outside Turn 1 wall with four laps remaining. This placed the crew chiefs for Busch and others running up front in a difficult position where they had to choose between pitting for fresh tires and foregoing track position, or staying out on older tires.
Newman, who was seventh, thought it best to pit and take two tires. Crew chief Luke Lambert thought otherwise. He wanted to go for the win, figuring that with so few laps left their best chance stood if they stayed out, thereby placing Newman in a position where he would need to play defense.
It was the only opportunity we had to win the race, Lambert said. I felt like doing it was going to yield a better result than the other option. Ultimately that was the decision. He said he could make the car wide. He did.
It was now Newmans race to win or lose. The key would be the restart. If he could get away cleanly and not have those behind on fresh tires get a run entering Turn 1, he stood a chance.
Newmans mind flashed back to late restart in last falls playoff race at Phoenix, when leader Matt Kenseth found himself in a similar position. On that day, Alex Bowman had been able to get to the inside of Kenseth, who came down and clipped Bowman sending him spinning. Logano would go on to win, while Kenseth not only lost the race but was also eliminated from the playoffs.
You're on old tires, it's easy to screw up, Newman said. You got to get your tires cleaned off right. You got to get a good launch. You got to run through the gearbox right. Then you got to hold everybody off.
The stakes werent as high Sunday as they were in November when a berth in the championship finale was on the line, but for a driver and team in the midst of a three-year-plus dry spell, what was before them carried considerable importance.
Kyle Larson had been second before the caution and after pitting he would be fourth, the highest-placed among drivers on fresh tires, and in the preferred outside groove. He would likely be Newmans biggest threat provided he didnt get bogged down in traffic.
That didnt occur.
When the green flag waved Newman did his part and edged ahead, but as anticipated Larson got a terrific restart and was closing. However, instead of exercising patience, Larson attempted to swing low and to the inside of Newman. Unbeknownst to Larson, Ricky Stenhouse Jr. was there and Larson cut across his nose just as Kenseth had done to Bowman last fall.
Hindsight is always 20/20, but I should have went a lane up in (Turns) 1 and 2, Larson said. I should have known to just stay close to Newman. That's what I wish I would have done.
To his credit, Larson didnt crash. The bobble, though, allowed Newman to build enough of a gap that there wasnt enough time to chase him down and make a pass.
For the first time since July 28, 2013, Newman was on his way to victory lane. And for the first time since Nov. 3, 2013, a RCR driver had picked up a Cup Series checkered flag.
Going a long time without winning, you have confidence in your mind that you can do it, Newman said. You just got to stay humble. This sport, you walk away from it, there's one guy that wins, 39 losers. You have to be humble walking into it that you're probably not going to win that day. Odds are against you.
On the surface it may appear as if Newman stole a race he had no business winning. That couldnt be farther from the truth.
It took a combination of sage strategy by Lambert and Newmans veteran savviness to make it happen. The other six teams ahead of Newman couldve employed the same strategy as Lambert and not pitted under the final caution. Yet, it was Lambert who made the correct call. And on worn tires, it wouldve really been easy for Newman to stumble on the restart.
Sunday may have been an upset, but dont think for a second that it wasnt earned.
More here:
NASCAR Phoenix recap: The anatomy of Ryan Newman's upset win - SB Nation
There might be hope for Jackson Avery (Jesse Williams) and April Kepner (Sarah Drew) after all!
Last week's episode of Grey's Anatomy saw the divorced pair open the door for a rekindled romance with a sexy hookup while in Montana on a case -- where they also met Jackson's estranged father (Eric Roberts). While the couple's future is still uncertain, Drew assured fans at PaleyFest on Sunday that Japril will always be together -- whether romantically or otherwise.
RELATED: 'Grey's Anatomy': Jackson Meets His Father and Reunites With April -- Are They Back Together?
"I think the main takeaway from that experience in Montana is that these two people... there's so much love there, there's so much respect there. They know each other so well," Drew said during the Grey's Anatomy panel. "Whether it continues and moves towards romance or stays platonic, we know for sure that these two are going to be okay, and that they're always going to depend on one another, and they will always be one another's person."
"At the end of the day, who knows [what will happen]?" she added.
Williams also commented on the pair's connection, calling April Jackson's "best friend."
"He has a great support system and an absolute failure in the same experience," he shared of the tense scene when Jackson comes face-to-face with his father. "He's doing it with the full support of his person, his best friend, April Kepner."
EXCLUSIVE: Sarah Drew on Juggling Greys Anatomy With Motherhood, Her TV Twins & Future of 'Japril'
"I was excited [for the scene]. It's been a big cloud over the character for his entire life, and my entire career playing him," Williams confessed. "It's been like, a big gaping hole, so being able to fill that in with a human being, with a person you can make eye contact with and ask all these questions... was a very exciting process."
"I really prepared myself by making sure I went over and understood my timeline, and what this character has been through, but also I was just really laid the table to be able to listen and be honest in the moment," he added.
Williams and Drew shot the episode on location in Montana, with Kevin McKidd (Owen Hunt) directing.
"We went off with Kevin to shoot episode 16 while all the rest of these guys were shooting episode 10 or 11, so we were shooting with the Scandal crew. We were working with a completely different crew, in a completely different set, on location. We were in the mountains," Drew revealed. "It really did feel like we were shooting a movie. It was really neat to get the chance to kind of get out of the hospital and follow just one specific story all the way through to the end, because we got the opportunity to really take time to listen."
"So much happened in the silence in that episode, which we just don't have the luxury for when we're servicing so many different storylines," she said. "So it was really amazing."
Photo: Getty Images
RELATED: Jesse Williams Slams Hollywood Whitewashing: 'The More Diverse a Movie Is, the More Money It Makes'
"I was so proud of Jesse and Sarah, and everyone... the work that we did," McKidd offered. "When I read that script, I wanted it to feel like an independent movie -- a really high end, quality independent movie. That was my approach."
"I really encouraged the actors to just breathe," he added, "and I think it turned into something beautiful."
While Jackson and his father hashed it out on Thursday's episode, there's clearly much more to the pair's story -- which Williams said he "would love" to explore.
"I really hope so, not just selfishly, for being able to work with such an incredibly talented actor [in Roberts]," he said. "I would love to. I think there's a lot left to do there."
RELATED: 'Grey's Anatomy,' 'Scandal' Picked Up for New Seasons
"We've planted a lot of seeds this season -- and that's one of them -- that resonate in a lot of ways," added Debbie Allen, who executive produces the series in addition to starring as Jackson's mother, Catherine Avery. "But there's more coming."
As for Williams and Drew's relationship in real life, the 35-year-old actor said it's "much more stable" -- though Ellen Pompeo and Justin Chambers arguably had the most chemistry on stage, as Chambers sweetly gave up his coat for his shivering co-star.
"We don't fight, and it's really helpful. I think that generally, it's a really lighthearted set. We crack a lot of jokes and have a lot of fun and try to save the drama for what's on screen," Williams admitted. "We're carrying that with us for weeks at a time to deliver, to serve it up to you, so it's a lot of heavy weight, a lot of drama, and drama that we're trying to figure out how to articulate for you. So we try to keep it light."
EXCLUSIVE: 'Grey's Anatomy' Stars Jesse Williams and Sarah Drew Say Jackson and April Will Find 'Happiness'
Read the original:
'Grey's Anatomy's Jesse Williams & Sarah Drew on That Japril ... - Entertainment Tonight
Science Daily | New 'gene silencer' drug reduce cholesterol by over 50 percent Science Daily The results from this trial, known as ORION-1, are published in the New England Journal of Medicine, and are presented today at the American College of Cardiology's 66th Annual Scientific Session in Washington. The authors say the results show the drug ... |
Follow this link:
New 'gene silencer' drug reduce cholesterol by over 50 percent - Science Daily
Fort Worth Star Telegram | Rangers clubhouse missing key players, but chemistry will be there Fort Worth Star Telegram For those who still believe in chemistry being a major component of the game and that's just about everyone in baseball, by the way the Rangers expect that the clubhouse will again be a strength despite the disruptive spring and the loss of three ... |
Read the original:
Rangers clubhouse missing key players, but chemistry will be there - Fort Worth Star Telegram
Usually when you hear the word chemical, you think of something synthetic, cooked up in a laboratory, but ingredients extracted from plants and minerals are chemicals too.
A natural ingredient is a chemical, and a synthetic one is also a chemical; it doesnt mean that just because its natural that it is necessarily best for you, Alice said.
For one company, its natural credentials might be used as its selling point, while for another its scientifically engineered compounds are touted as the best for your skin. Both approaches can be misleading and are a source of frustration for Alice.
If youre thinking about the interaction with the body, where a particular chemical comes from is not necessarily going to give you a good indication about whether it is good for you or not, you actually have to look at that interaction, she said.
Our bodies are built on chemistry; everything in us is chemistry.
Look at the ingredients label on a typical moisturiser or shampoo and there will likely be a list of unintelligible chemical names, which most of us wont have a clue what they are. But theres a growing interest among consumers, and safety concerns about certain ones have been raised in recent years.
SLS and parabens, for example, while considered safe by the EU, have been cited as possible hormone disrupters and irritants. As a result, you might have spotted SLS-free or paraben-free labels on some of your favourite products.
Because of strict UK and EU regulations that govern what can go into our food and cosmetic products, and extensive safety testing, Alice thinks consumers should not be overly worried.
But, without mentioning any ingredients in particular, she does suggest, It is a question of keeping an eye on the research and seeing whether those things do turn out to be bad for us or not. We see changes in the regulations all the time as new research is done, looking in detail at particular compounds.
If there is concern about a particular compound, you can always apply the precautionary principle and avoid them, but you have to be careful you dont get paranoid about it.
Ethics and The Environment
When it comes to buying both everyday and luxury cosmetic products for herself, Alice says ethics plays a big role in her choices.
If youre buying something like that, it is really important to know it is ethical and youre buying something that feels luxurious and is lovely for you, but youre doing it with concern for the environment and with concern for all the people whove been involved in it as well, she said.
Dr Alice Roberts
So this year, Alice is working with organic beauty brand Green People as their official adviser on science communication to get all of us thinking about the chemistry of everyday products.
For me public engagement with science is about having a much more open and wider discussion about science and technology and also making sure that you are providing information to people in an accessible way, said Alice, who is also professor of Public Engagement in Science at the University of Birmingham.
Its really important that there is dialogue between scientists and the general public; its about sharing information more effectively and being able to make decisions about where science is going in the future,where technology is going in the future, as a society. We need to make sure that we are much more scientifically literate as a society.
As a long-time user of Green Peoples products, she is proud to be an ambassador for a company that has rigorous organic, fair trade and environmental policies and have always put a lot of scientific research intotheir products.
The fact [Green People] have this ethical concern about the impact on the environment and people so they are concerned about making sure they are using fair trade sourced ingredients, making sure they are as ethical as they can be with their ingredients I think that is great, said Alice.
And, of course, they dont test on animals, a practice Alice finds puzzling. I am just very confused by the fact that cosmetics have ever been tested on animals; it is such a peculiar thing to do if you dont need to do it and you dont need to do it.
For me, the fact that for Green People [no animal testing] has been a central tenet of the way that they work and that they wouldnt now aim to sell products in countries which are asking for products to be tested on animals, I think that is really important for my own personal ethics.
While animal testing for cosmetics is banned in the EU, China, however, currently requires all imported cosmetic products to have undergone such testing.
Continued here:
The chemistry of beauty - The Epoch Times
Market Summary Follow
Puma Biotechnology Inc is a A biopharmaceutical company
PBYI - Market Data & News
PBYI - Stock Valuation Report
Puma Biotechnology Inc (PBYI) traded on unusually high volume on Mar. 17, as the stock gained 0.91% to close at $44.15. On the day, Puma Biotechnology Inc saw 2.2 million shares trade hands on 7,459 trades. Considering that the stock averages only a daily volume of 1.19 million shares a day over the last month, this represents a pretty significant bump in volume over the norm.
Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.
The stock has traded between $73.27 and $19.74 over the last 52-weeks, its 50-day SMA is now $35.79, and its 200-day SMA $42.49. Puma Biotechnology Inc has a P/B ratio of 7.77.
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.
Headquartered in Los Angeles, CA, Puma Biotechnology Inc has 160 employees and is currently under the leadership of CEO Alan H. Auerbach.
For a complete fundamental analysis analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.
Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.
To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer
See original here:
Puma Biotechnology Inc (PBYI) Moves Higher on Volume Spike for March 17 - Equities.com
NEWS Brooks Pate wins Edlich-Henderson Innovator of the Year award by Yae Ji Cha | Mar 17 2017 | 5 hours ago
Chemistry Prof. Brooks Pate has won the Universitys highest award for faculty innovation. The Universitys Licensing & Ventures Group, which seeks to turn ideas and discoveries from the University into marketable products, has awarded Pate with the Edlich-Henderson Innovator of the Year award.
Pates research on molecular analysis has led to the creation of a new scientific instrument that significantly reduces the time and cost needed to perform complex chemical analysis. His research discovery on molecular rotational spectroscopy played an integral role in the founding of the local lab firm, BrightSpec, which helped turn the research into an instrument for scientists to use.
Pate said their research on molecular rotational spectroscopy measures how fast molecules rotate.
The idea is that the sensors become like a molecular ice skater, where the shape of the ice skater determines how fast they rotate, Pate said. We measure the frequency to very high accuracy, about eight digits of accuracy. From how fast they rotate, we can back out what their three dimensional geometry was.
Pates research opens new applications for scientists because it advances the ability of those measurements to get information on more challenging systems. The technique theyve developed, chirped pulse spectroscopy, allows measurements to be taken 10,000 times faster than theyve been made before.
The advantage of that is essentially going faster [which] means that at some level youre more sensitive, Pate said. And that really allowed us to open up the technique to look at some relatively challenging problems and how molecules clump together when they come together to form assemblies of molecules and thats been a very hard measurement to make.
Brightspec CEO Bob Lloyd helped to bring Pates research into the marketplace. Brightspecs clients include mostly research groups both federal and academic in the U.S. and Europe and is working to expand into the commercial pharmaceutical industry.
Lloyd said he wanted to work with Pate for several reasons, including the fact there were three graduate students working in Pates lab who were trained in the technique and were looking for a full-time career. Pates prototype was also a motivating factor for the partnership.
And that prototype, that working prototype, we were able to take around to conferences and gauge peoples reactions to it, Lloyd said.
Three patents were also established and they found people to use the product around the U.S.
At the end of that process we had all the components we needed to start a company, Lloyd said. We had a team, a prototype, IP and people who said they cared from the customer segment.
Pate credited his award to the involvement of the three graduate students in his work.
They were able to perfect the instrument and start filling the instruments to companies who were looking for new ways to do chemical analysis, Pate said. The award really comes from the effort of my students company, and the fact that theyve been able to take these ideas and create instruments that people can use to solve problems that they couldnt solve before.
In the future, Pate will be working more with the concept of isotopic abundances, which might have the potential to explain the origins of molecules.
Were now really focused on trying to bring new solutions to the problem of being able to measure isotopic abundances in molecules the high accuracy, Pate said. [This isotopic signature] is something that people think will be very important in identifying where molecules come from.
See the article here:
Chemistry professor wins top prize for faculty entrepreneurship - University of Virginia The Cavalier Daily
EW.com | 'Grey's Anatomy' recap: 'Who Is He (And What Is He to You)?' EW.com Here's one thing you should know: Jackson doesn't make promises he can't keep. He makes this known in his various monologues throughout this episode, where he and April jet off to Montana for a quick trip to perform surgery on a couple of kids who can ... Grey's Anatomy Season 13 Episode 16: "Who Is He (And What Is He To You)?" 'Grey's Anatomy' Stars Jesse Williams and Sarah Drew on April and Jackson's Big Step Forward Grey's Anatomy Recap: #Japril Goes to Montana |
Read more:
'Grey's Anatomy' recap: 'Who Is He (And What Is He to You)?' - EW.com
PORTSMOUTH Shawnee State University offers help for any student enrolled in a chemistry class at the Chemistry Study Center, located in Room 341 in Massie Hall.
The Chemistry Study Center employs SSU students as their tutors who are able to help in the following chemistry classes: Preparation for College Chemistry, Principles of Chemistry, General Chemistry 1 and 2, Intro to Organic Chemistry, and Organic Chemistry 1 and 2. No appointments are necessary, but a list of the tutoring schedule can be found online at http://www.ssuscience.com/csc/csc.html.
The Chemistry Study Center tutors will be able to help with a number of chemistry problems, including balancing chemical equations, conversions, defining chemistry terms and more.
The study center is great place for students to come if they just have a question, or need help with lab reports, or even just to study for any of their chemistry classes, said Dr. Andrew Napper, Professor of Chemistry and Chair of the Department of Natural Sciences. Since it is staffed by student tutors, it is less intimidating for them to reach out for help.
Read more:
Chemistry Study Center open to Shawnee State students - Jackson County Times-Journal